Beeinflussung des Internationalen Prostata-Symptomen-Score unter der Therapie mit Sägepalmenfrüchteextrakt bei täglicher Einmalgabe

Derakhshani, P.; Geerke, H.; Bohnert, K.-J.; Engelmann, U.

doi:10.1007/s001310050101

Cited by 5 publications

(6 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The changes in the IPSS, QoL, and Qmax from baseline to 3 months were: −7.4 (40.4%), −1.61 (45.9%), and +3.7 mL/s (30.8%), respectively. Specifically, for Qmax, 16% of patients went from a baseline of 12.0 mL/s to above 18 mL/s [19]. Recall that in the Barry 2011 study [110], the use of Prosta-Urgenin Uno was no better than placebo.…”

Section: The Onset Of Luts Response To Lsesr Occurs As Early As 4 Weeksmentioning

confidence: 98%

“…The mean number of patients in the evaluable non-English-language studies for LSESr for efficacy in LUTS was 460, influenced by the Vahlensieck 1993 study with 1334 patients [16], the Derakhshani 1997 study with 1047 patients at the study end [19] and the Eickenberg 1997 study with 6967 patients [20]. The mean study duration across the 27 evaluable non-English-language papers was 12 months, influenced by Aliaev 2002 (60 months) [26], Breza 2005 (12 months) [33], Aliaev 2009 (24 months) [30], Vinarov 2010 (36 months) [31], and especially Aliaev 2013 (120 months) [32].…”

Section: Search Strategy and Selection Criteria Were Pivotal To Perspective On Lsesr Vs Lutsmentioning

confidence: 99%

“…This decrease was maintained for the 12-month duration of the study, with Permixon showing a total IPSS decrease of −5.9 points vs. a tamsulosin drop of 6.0 points. In the Derakhshani et al 1997 study of 1047 patients from 357 practices, Prosta-Urgenin Uno, an EESr, was given at a dose of 320 mg/day for 3 months [19]. At baseline, 15% of patients reported no nocturia, but after 6 weeks, the percentage of patients without nocturia increased to 38% and was absent in 54% at 3 months.…”

Section: The Onset Of Luts Response To Lsesr Occurs As Early As 4 Weeksmentioning

confidence: 99%

See 2 more Smart Citations

Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part II

Strum

2021

Uro

View full text Add to dashboard Cite

Part I of this 3-part series provided the groundwork for understanding the role of a standardized lipidosterolic extract of Serenoa repens (LSESr) in the treatment of LUTS. It documented that a treatment having a high therapeutic index (i.e., a ratio of benefit to adverse reactions) is a critical need in the demographic context of a rapidly growing elder population. Part I described the clinical symptomatology of LUTS and how it is quantified. A critique of the reports from four authoritative bodies: the European Scientific Cooperative on Phytotherapy (ESCOP), Cochrane 2012, the European Medicines Agency (EMA), and the AUA (American Urological Association) was presented. The foundation above then fine-tuned our search to require (a) consistent evaluability criteria, (b) the quantification of clinical findings, (c) the need to focus on studies employing a standardized LSESr product meeting the fatty acid profile set forth by the European Medicines Agency (EMA) and the US Pharmacopeia and (d) a global assessment of scientific investigations published in all languages and not limited to only English. With the above four constraints, “new” findings about LSESr vs. LUTS are presented. How did the search strategy and selection criteria lead to new understandings about the role of LSESr vs. LUTS? How safe is LSESr in contrast to its counterpart prescription drugs? Of the proposed major mechanisms of action of LSESr (e.g., 5-alpha reductase inhibition and anti-inflammatory activity), what are the key points? After initiating treatment with LSESr, when is clinical improvement seen? How durable is LSESr in ameliorating LUTS? Can LSESr prevent the progression of BPH?

show abstract

Section: The Onset Of Luts Response To Lsesr Occurs As Early As 4 Weeksmentioning

confidence: 98%

Section: Search Strategy and Selection Criteria Were Pivotal To Perspective On Lsesr Vs Lutsmentioning

confidence: 99%

Section: The Onset Of Luts Response To Lsesr Occurs As Early As 4 Weeksmentioning

confidence: 99%

See 1 more Smart Citation

Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part II

Strum

2021

Uro

View full text Add to dashboard Cite

show abstract

“…The Barry study selected an ethanolic extract of Serenoa repens (EESr) called Prosta Urgenin Uno ® (Rottapharm/Madaus), with results indicating it to be no better than placebo using the AUA-SI as the objective endpoint [15]. In an earlier large 3-month intervention study by Derakhshani et al [47] but not discussed by Barry et al, Prosta Urgenin Uno was used in 1047 patients from 357 urologic practices. At study end, Derakhshani reported an overall mean change in IPSS of −7.4 points, representing a 40% improvement; a QoL change of −1.61, representing a 45.9% improvement; and a Q max increase after 3 months of +3.7 mL/s for a 30.8% improvement.…”

Section: The Cochrane Meta-analysis (Cochrane 2012)mentioning

confidence: 99%

Serenoa repens (Saw palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part I

Strum

2021

Uro

View full text Add to dashboard Cite

Lower urinary tract symptoms (LUTS) are classically characterized as being related to storage (e.g., frequency, urgency, and nocturia) or flow (e.g., weak stream, intermittency, straining, and incomplete emptying). Conventional prescription medications such as α1-blockers and 5α-reductase inhibitors are used to treat progressive LUTS in men. Due to the adverse events associated with these prescription drugs, many patients with mild-to-moderate LUTS may decide to initiate treatment with non-prescription medications and/or dietary supplements. The lipidosterolic extract of Serenoa repens (LSESr), at a recommended daily dose of 320 mg/day, has been the focus of numerous peer-reviewed studies and review articles concerning the treatment of LUTS, from the first publication in 1983 by Boccafoschi to the most recent publication in 2021 by Russo. Although it seems improbable that the beneficial effect of LSESr reflects a placebo effect given the consistent degree of efficacy comparing various studies published in different countries over a span of almost 40 years, this has been the prevailing impression stemming from essentially three publications in the Western medical literature. In addition, despite publications reporting findings of almost identical efficacy using LUTS endpoints such as the International Prostate Symptom Score (IPSS), the quality of life score (QoL), and the peak urinary flow (Qmax) in comparing LSESr with the α-blocker tamsulosin or the 5α-reductase inhibitor finasteride, and despite the recognized acceptance of the hexane lipidosterolic extract product (Permixon®) as an herbal medicine in Europe showing value in the treatment of LUTS, the use of LSESr remains controversial in the US. Contributing to such an opposing view in the US are the wide variability in quality, composition, and dosage of Serenoa products, the commercial prevalence of dried berry powder supplements, and the lack of awareness of a standardized Serenoa phytotherapy lipidosterolic profile. Can the controversy over the efficacy of LSESr in the context of LUTS be resolved? By understanding the main literature that has led to clinical practice guidelines for Serenoa repens for LUTS in Europe and the US, and by an in-depth analysis of the totality of the clinical literature concerning dose, extraction method, and quality of the Serenoa product used, it should be possible to answer this question. Given the extent of this global analysis, this report is presented in three sections. Part I introduces LUTS. What are the demographics of LUTS? What symptoms are assessed by LUTS, and how do we quantify LUTS? Why would a non-prescription item be a valuable consideration in LUTS treatment versus other treatment options? What is basic information about Serenoa repens, and what defines a standardized LSESr product? What are the published trials that have affected the acceptability of Serenoa repens in the treatment of LUTS? Finally, a major portion of Part I discusses the four major reviews of Serenoa repens versus LUTS that have influenced how it is accepted in the USA, in Europe, and in other parts of the world. Part I, therefore, lays the groundwork and is foundational for the important findings relating to LUTS and Serenoa repens that will be presented as Parts II and III in subsequent review articles.

show abstract

“…Toxic effect. Ethanol (95%) extract of the dried fruit, administered to adult males at a dose of 320 mg/day, was inactive SR091,SR095 . Ether extract of the fruit, administered orally to male adults at a dose of 320 mg/ day, was inactive SR090,SR093,SR031 .…”

Section: Lymphohistiocytic Adenoma Activitymentioning

confidence: 99%

Serenoa repens

Medicinal Plants of the World, Volume 3

View full text Add to dashboard Cite

DISTRIBUTIONThis palm is native to the southeastern United States, from Florida to North Carolina. It grows in coastal dune areas and inland pine woodlands, often forming dense, impenetrable thickets in the understory of pines, such as slash pine (Pinus elliottii) and longleaf pine (Pinus palustris).TRADITIONAL MEDICINAL USES Germany. The fruit is taken orally as a source of estrogen SR077 . North America. Hot water extract of the fruit is taken orally as a sedative SR127 . United States. Hot water extract of the fruit is taken orally for prostate inflammation SR123 and for benign prostatic hyperplasia SR098,SR109 . Fluid extract of the fruit is taken orally for dysmenorrhea SR126 . Hot water extract of the fruit is used to treat colds and for irritated throat. A teaspoon of berries in a cup of boiling water is cooled and taken 1 or 2 cups a day SR128 .

show abstract

Beeinflussung des Internationalen Prostata-Symptomen-Score unter der Therapie mit Sägepalmenfrüchteextrakt bei täglicher Einmalgabe

Cited by 5 publications

References 7 publications

Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part II

Serenoa Repens (Saw Palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part II

Serenoa repens (Saw palmetto) for Lower Urinary Tract Symptoms (LUTS): The Evidence for Efficacy and Safety of Lipidosterolic Extracts. Part I

Serenoa repens

Contact Info

Product

Resources

About